ATyr Pharma will present a poster at the 2022 European Respiratory Society International Congress

SAN DIEGOaTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company committed to the discovery and development of first-in-class drugs from its proprietary tRNA synthetase platform, today announced that the company will present a poster on Monday, September 5, 2022of 8:30 a.m. – 9:30 a.m. CEST to International Congress of the European Respiratory Society (ERS) 2022 in Barcelona, ​​Spain.

The corresponding abstract and electronic poster are available on the conference website. The poster will be available on the aTyr website once presented.

The poster presents the results of a highly selective and sensitive antibody for the immunohistochemical (IHC) detection of neuropilin-2 (NRP2) protein in patient tissue samples. NRP2 is a cell surface receptor that has been identified as the binding partner of efzofitimod, a new immunomodulator in clinical development for the potential treatment of pulmonary sarcoidosis and other forms of interstitial lung disease (IPD). The antibody was found to be highly specific for NRP2 and was used to demonstrate high level expression of the NRP2 protein in granulomas from skin and lung biopsy specimens from patients with sarcoidosis.

“This unique antibody developed by the aTyr research team and optimized for IHC in collaboration with the Muders laboratory provides a highly specific and sensitive detection method for NRP2 that will facilitate the characterization of the target efzofitimod receptor in samples from patient tissue,” said Leslie A.Nangle, Ph.D., Vice President, Research at aTyr. “This may provide an extremely useful clinical tool, potentially aiding in patient selection or stratification, thereby enabling a thoughtful understanding of NRP2 expression with respect to relevant disease states, in sarcoidosis, other diseases interdandruff, oncology and other indications in which this receptor plays a role.’

About efzofitimod

aTyr is developing efzofitimod as a potential therapeutic agent for patients with fibrous lung disease. Efzofitimod, a fusion protein composed of the immunomodulatory domain of histidyl-tRNA synthetase fused to the FC region of a human antibody, is a selective neuropilin-2 modulator that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr’s primary indication for efzofitimod is pulmonary sarcoidosis, a major form of interstitial lung disease. Clinical proof of concept for efzofitimod was recently established in a placebo-controlled, multiple ascending dose Phase 1b/2a study of efzofitimod in patients with pulmonary sarcoidosis, which demonstrated the safety and consistent dose-response and benefit trends of efzofitimod versus placebo on key efficacy endpoints including steroid reduction, lung function, clinical symptoms, and inflammatory biomarkers. aTyr is currently conducting EFZO-FIT, a Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

About aTyr

aTyr is a biotherapeutics company engaged in first-in-class drug discovery and development based on its proprietary tRNA synthetase platform. aTyr’s research and development efforts focus on a recently discovered area of ​​biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property portfolio directed towards a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr is primarily focused on efzofitimod, a clinical-stage product candidate that binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified by the use of words such as “anticipates”, “believes”, “estimates”, “would expects, ‘intends’, ‘may’, ‘plans’, ‘plans’, ‘seeks’, ‘should’, ‘will’ and variations of these words or similar expressions. We intend that these forward-looking statements be covered by these safe harbor provisions for forward-looking statements and make this statement in order to comply with these safe harbor provisions. These forward-looking statements include statements regarding the potential therapeutic benefits and applications of efzofitimod; timelines and plans for certain development activities (such as timing of clinical trials) and certain development goals. These forward-looking statements also reflect our current beliefs about our plans, intentions, expectations, strategies and prospects, which are based on information currently available to us and assumptions made by us.

Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected or implied by these forward-looking statements, are reasonable, we cannot guarantee that the plans, intentions, expectations or strategies will be achieved or realized. All forward-looking statements are based on our management’s estimates and assumptions which, although we believe to be reasonable, are inherently uncertain. In addition, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors beyond our control, including, without limitation, uncertainty regarding the COVID-19 pandemic. 19, the risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners stop or delay preclinical or clinical development activities of any of our existing or future product candidates for various reasons (including difficulties or delays in recruiting patients into trials), the possibility that existing collaborations may be terminated prematurely, and the risk that we may not be able to raise additional funds required for our business plans and product development, as well as the risks set forth in our Quarterly Report on Form 10-Q for the t term completed June 30, 2022 filed with the SECOND on August 15, 2022 and in our other SECOND deposits. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Ashlee Dunton

Email: [email protected]


Source link

Comments are closed.